Back to today’s briefing

Story perspectives

Gilead and Kymera Launch $750M Cancer Therapy Partnership

6/27/2025

33 7

Summary

Story summary

Gilead Sciences and Kymera Therapeutics have forged a groundbreaking $750 million partnership to create oral molecular glue degraders aimed at CDK2, a protein implicated in breast cancer and other solid tumors. This cutting-edge strategy seeks to selectively eliminate CDK2, paving the way for safer, more effective cancer therapies. Kymera will spearhead the research, with Gilead poised to secure global rights.

1 of 1

Story summary

Gilead Sciences and Kymera Therapeutics have forged a groundbreaking $750 million partnership to create oral molecular glue degraders aimed at CDK2, a protein implicated in breast cancer and other solid tumors. This cutting-edge strategy seeks to selectively eliminate CDK2, paving the way for safer, more effective cancer therapies. Kymera will spearhead the research, with Gilead poised to secure global rights.